Results 141 to 148 of about 5,545 (148)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma

Journal of Allergy and Clinical Immunology, 2017
Steven W Yancey, Hector G Ortega, Oliver N Keene   +2 more
exaly  

Mepolizumab—a novel option for the treatment of hypereosinophilic syndrome in childhood

Pediatric Allergy and Immunology, 2018
Carsten Schwarz, Susanne Lau, Doris Staab   +2 more
exaly  

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2019
Kenneth R Chapman, Frank C Albers, Xavier Munoz   +2 more
exaly  

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

Respiratory Medicine, 2019
Frank C Albers, Christopher Licskai, Eric S Bradford   +2 more
exaly  

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Pediatric Pulmonology, 2019
Atul Gupta, Rodger Kempsford, Jonathan Steinfeld   +2 more
exaly  

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Allergy: European Journal of Allergy and Clinical Immunology
Dennis Thomas, Andrew Gillman, Mark Hew   +2 more
exaly  

Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology
Michael Fricker, John Harrington, Peter G Gibson   +2 more
exaly  

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects

Clinical Pharmacology in Drug Development, 2016
exaly